No Correlation of Intensity of Phlebotomy Regimen With Risk of Thrombosis in Polycythemia Vera: Evidence From ECLAP and CYTO-PV Clinical Trials

The conclusions obtained from this meta-analysis indicate that the frequency of phlebotomies in patients with polycythemia vera receiving hydroxyurea does not represent a risk factor for future thrombosis in patients with polycythemia vera and does not support the need to shift from hydroxyurea plus therapeutic phlebotomy to second-line agents, and indirectly reinforce that a low HCT is the key variable to reduce the thrombotic risk in PV patients. 


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.